Abstract
The attention deficit with hyperactivity disorder is the most frequent disorder in pediatric outpatient services and its treatment involves behavioral therapy and drugs. However, there is concerning about develop substances use disorder once upon treatment with stimulants. Medicine based evidence suggests a preventive effect about psychoactive substance consumption but also warns potential abuse by patients and people around. In this paper, we systematically review worths and risks of SUD in stimulant - treated ADHD patients.
References
Barbaresi WJ, Katusic SK, Colli. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med. 2002; 156: 217-224.
Raishevich N, Jensen PS. Attention deficit/hyperactivity disorder. In: Kliegman RM, Stanton BF, Geme JS, Schor NF, Behrman RE. Nelson Texbook of Pediatrics.18TH edition. Philadelphia: Saunders Elsevier Press; 2007. P 146-150.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, 2013; 59-61.
Loney J, Milich M. Hyperactivity, inattention and aggression in clinical practice. In Wolraich M, Routh DK, eds. Advances in Behavioral and Developmental Pediatrics. Greenwich, CT: Jessica Kingsley Pub; 1982. P. 113-147.
Cornejo W Osío O, Sánchez Y, Carrizosa J, Sánchez G, Grisales H, et al; Prevalencia del trastorno por déficit de atención- hiperactividad en niños y adolescentes colombianos. Rev Neurol 2005; 40:716-22.
Bastidas M, Posada A, Ramirez H. Crecimiento y desarrollo del niño escolar. En: Posada A, Gómez JF, Ramírez H. 5a Edición. El niño sano. Medellín, Colombia: Editorial. Médica Panamericana. 2005. P 151-160.
Bradley C. Behavior of children receiving benzedrine. Am J Psychiatry 1937; 94: 577-585.
Patrick KS, Straughn AB, Perkins JS, González MA. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Human Psychopharmacology 2009; 24: 1-17.
Durukan I, Turbay T, Congologlu A. The effects of methylphe-nidate on various components of visual attention in children with attention deficit hyperactivity disorder. Turkish Journal of Psychiatry. 2008; 19 (4): 358-364.
Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007; 46(8): 989-1002.
Chait LD. Reinforcing and subjective effects of methylpheni-date in humans. Behav Pharmacol. 1994. 5:281-288.
Fredericks EM1, Kollins SH. Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology (Berl). 2004; 175(4):391-8.
Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron 2002; 36: 229-240.
Grant BF, Dawson DA. Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: results from National Longitudinal Alcohol Epidemiologic Survey. J subst Abuse. 1997; 9: 103-110.
Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006; 163(4): 716-723.
Biederman J. Pharmacotherapy for attention-deficit/hyperac-tivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 2003; (64 Suppl 11): 3-8.
Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011 Apr; 31(3):328-41.
Annabeth P. Groenman, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk developing substance disorder. The British Journal of Psychiatry. 2013. 203(2): 112-119.
Harstad E, Levy Sharon. Attention-Deficit/Hyperactivity Disorder and Substance Abuse. Pediatrics 2014:134: e293.
Spencer T, Biederman J, Wilens T. Attention-deficit/hyperac-tivity disorder and comorbidity. Pediatr Clin North Am. 1999; 46(5): 915-27.
Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000 Jan; 9(1): 77-97.
Kollins SH. ADHD, substance use disorders, and psychostimu-lant treatment: current literature and treatment guidelines. J Atten Disord. 2008 Sep; 12(2): 115-25.
Loney J, Klahn M, Kosier T, Conboy J. Hyperactive boys and their brothers at 21: predictors of aggressive and antisocial outcomes. In: Van Dused KT, Mednick SA. Prospective Studies of Crime and Delinquency. Hingham, MA: Kluwere/Nijhoff; 1982. P. 181-207.
Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998; 31: 533-544.
Paternite CE, Loney J, Salisbury H, Whaley MA. Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. J Child Adolesc Psychopharmacol. 1999; 9(3): 169-84.
Wilens T. Attention deficit hyperactivity disorder and substance use disorders-the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004; 27(2): 283-301.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.